{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:27:56Z","timestamp":1784348876619,"version":"3.55.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017559","name":"Recordati Rare Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017559","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Over the past 10\u2005years, osilodrostat has become one of the most commonly used steroidogenesis inhibitors in patients with Cushing's syndrome. The starting dose is usually determined based on the product characteristics, the prescriber's experience, and cortisol levels. However, no study has attempted to determine whether there was a dose\u2013response relationship between osilodrostat and cortisol reduction. In this study, we developed a preliminary kinetic\u2013pharmacodynamic model to tailor osilodrostat in patients with Adrenocorticotropin hormone (ACTH)-dependent Cushing's syndrome. We first analyzed the decrease in cortisol 48\u2005hours after initiation or dose change of osilodrostat in 18 patients. Simulations were then performed for different doses of osilodrostat to evaluate the variation in cortisol concentrations. Our results report the first dose\u2013response relationship between osilodrostat dose and cortisol levels, which should be helpful in identifying the optimal dosing regimen in patients with Cushing's syndrome and in individualizing treatment to approximate a nychthemeral rhythm.<\/jats:p>","DOI":"10.1093\/ejendo\/lvaf185","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T21:35:17Z","timestamp":1758317717000},"page":"K11-K15","source":"Crossref","is-referenced-by-count":5,"title":["A preliminary model to tailor osilodrostat in patients with Adrenocorticotropic hormone (ACTH)-dependent Cushing's syndrome"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9843-5308","authenticated-orcid":false,"given":"Cecilia","family":"Piazzola","sequence":"first","affiliation":[{"name":"INSERM, MMG, Department of Endocrinology, La Conception Hospital, Assistance Publique Hopitaux de Marseille, Aix Marseille University , Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1808-8800","authenticated-orcid":false,"given":"Frederic","family":"Castinetti","sequence":"additional","affiliation":[{"name":"INSERM, MMG, Department of Endocrinology, La Conception Hospital, Assistance Publique Hopitaux de Marseille, Aix Marseille University , Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"von Fabeck","sequence":"additional","affiliation":[{"name":"INSERM, IRD, SESSTIM, Sainte Marguerite Hospital, Clinical Pharmacology and Poison Control Centre, Aix Marseille University , Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Simon","sequence":"additional","affiliation":[{"name":"INSERM, IRD, SESSTIM, Sainte Marguerite Hospital, Clinical Pharmacology and Poison Control Centre, Aix Marseille University , Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"issue":"2","key":"2025100107011320400_lvaf185-B1","doi-asserted-by":"publisher","first-page":"101381","DOI":"10.1016\/j.beem.2020.101381","article-title":"Cushing's syndrome: treatment and new therapeutic approaches","volume":"34","author":"Ferriere","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"issue":"12","key":"2025100107011320400_lvaf185-B2","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing's disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"2025100107011320400_lvaf185-B3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s11102-022-01244-w","article-title":"Cushing's disease: role of preoperative and primary medical therapy","volume":"25","author":"Castinetti","year":"2022","journal-title":"Pituitary"},{"issue":"11","key":"2025100107011320400_lvaf185-B4","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1210\/jc.2015-2616","article-title":"Effectiveness of metyrapone in treating Cushing's syndrome: a retrospective multicenter study in 195 patients","volume":"100","author":"Daniel","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2025100107011320400_lvaf185-B5","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2013-3628","article-title":"Ketoconazole in Cushing's disease: is it worth a try?","volume":"99","author":"Castinetti","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2025100107011320400_lvaf185-B6","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s12967-014-0340-9","article-title":"Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects","volume":"12","author":"M\u00e9nard","year":"2014","journal-title":"J Transl Med."},{"issue":"6","key":"2025100107011320400_lvaf185-B7","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s11102-022-01280-6","article-title":"Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a phase II study with an optional extension phase (LINC 2)","volume":"25","author":"Fleseriu","year":"2022","journal-title":"Pituitary"},{"issue":"9","key":"2025100107011320400_lvaf185-B8","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2025100107011320400_lvaf185-B9","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1007\/s40618-024-02359-6","article-title":"Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the phase III LINC 3 trial in Cushing's disease","volume":"47","author":"Pivonello","year":"2024","journal-title":"J Endocrinol Invest."},{"issue":"7","key":"2025100107011320400_lvaf185-B10","doi-asserted-by":"publisher","first-page":"e2882","DOI":"10.1210\/clinem\/dgac178","article-title":"Randomized trial of osilodrostat for the treatment of Cushing disease","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab."},{"key":"2025100107011320400_lvaf185-B11"},{"key":"2025100107011320400_lvaf185-B12","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2024"},{"key":"2025100107011320400_lvaf185-B13","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2","author":"Wickham","year":"2016"},{"key":"2025100107011320400_lvaf185-B14","doi-asserted-by":"publisher","author":"Fidler","DOI":"10.32614\/CRAN.package.rxode2"},{"key":"2025100107011320400_lvaf185-B15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/B978-0-7020-4299-7.00010-X","volume-title":"Drug Discovery and Development","author":"Ballard","year":"2013","edition":"2nd ed"},{"key":"2025100107011320400_lvaf185-B16","doi-asserted-by":"publisher","first-page":"dgaf206","DOI":"10.1210\/clinem\/dgaf206","article-title":"Chronotherapy with once-daily osilodrostat improves cortisol rhythm, quality of life, and sleep in Cushing's syndrome","author":"Ferrari","year":"2025","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2025100107011320400_lvaf185-B17","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.tem.2019.07.008","article-title":"Impact of circadian disruption on cardiovascular function and disease","volume":"30","author":"Chellappa","year":"2019","journal-title":"Trends Endocrinol Metab."},{"issue":"2","key":"2025100107011320400_lvaf185-B18","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1210\/jc.2011-1926","article-title":"Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation","volume":"97","author":"Johannsson","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2025100107011320400_lvaf185-B19","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1530\/EJE-22-0317","article-title":"Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension","volume":"187","author":"Fleseriu","year":"2022","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2025100107011320400_lvaf185-B20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/cen.12259","article-title":"High variability in baseline urinary free cortisol values in patients with Cushing's disease","volume":"80","author":"Petersenn","year":"2014","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"1","key":"2025100107011320400_lvaf185-B21","doi-asserted-by":"publisher","first-page":"L1","DOI":"10.1093\/ejendo\/lvad167","article-title":"Prolonged adrenal insufficiency following discontinuation of osilodrostat treatment for intense hypercortisolism","volume":"190","author":"Ferriere","year":"2024","journal-title":"Eur J Endocrinol."}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvaf185\/64284744\/lvaf185.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/4\/K11\/64284744\/lvaf185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/4\/K11\/64284744\/lvaf185.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T11:01:25Z","timestamp":1759316485000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/193\/4\/K11\/8255719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvaf185","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,16]]}}}